Chidozie Ugwumba Sells 72,748 Shares of Clene (NASDAQ:CLNN) Stock

Clene Inc. (NASDAQ:CLNN) major shareholder Chidozie Ugwumba sold 72,748 shares of the business’s stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $6.73, for a total value of $489,594.04. Following the completion of the transaction, the insider directly owned 521,620 shares in the company, valued at approximately $3,510,502.60. This represents a 12.24% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Chidozie Ugwumba also recently made the following trade(s):

• On Wednesday, December 3rd, Chidozie Ugwumba sold 56,577 shares of Clene stock. The stock was sold at an average price of $7.86, for a total value of $444,695.22.
• On Thursday, December 18th, Chidozie Ugwumba sold 5,816 shares of Clene stock. The shares were sold at an average price of $6.33, for a total transaction of $36,815.28.
• On Wednesday, December 17th, Chidozie Ugwumba sold 2,884 shares of Clene stock. The stock was sold at an average price of $6.61, for a total transaction of $19,063.24.
• On Tuesday, December 16th, Chidozie Ugwumba sold 7,030 shares of Clene stock. The shares were sold at an average price of $6.31, for a total transaction of $44,359.30.
• On Monday, December 15th, Chidozie Ugwumba sold 10,580 shares of Clene stock. The stock was sold at an average price of $6.49, for a total transaction of $68,664.20.
• On Friday, December 12th, Chidozie Ugwumba sold 7,603 shares of Clene stock. The shares were sold at an average price of $6.79, for a total value of $51,624.37.
• On Thursday, December 11th, Chidozie Ugwumba sold 10,907 shares of Clene stock. The stock was sold at an average price of $6.81, for a total value of $74,276.67.
• On Wednesday, December 10th, Chidozie Ugwumba sold 9,921 shares of Clene stock. The shares were sold at an average price of $6.42, for a total value of $63,692.82.
• On Tuesday, December 9th, Chidozie Ugwumba sold 15,031 shares of Clene stock. The stock was sold at an average price of $5.95, for a total value of $89,434.45.
• On Monday, December 8th, Chidozie Ugwumba sold 21,463 shares of Clene stock. The shares were sold at an average price of $5.70, for a total transaction of $122,339.10.

Clene Stock Up 10.6%

CLNN opened at $6.68 on Friday. The firm has a 50-day moving average price of $8.51 and a 200-day moving average price of $6.21. Clene Inc. has a twelve month low of $2.28 and a twelve month high of $13.50. The company has a market capitalization of $69.00 million, a price-to-earnings ratio of -1.97 and a beta of 0.79.

Clene (NASDAQ:CLNN) last issued its earnings results on Thursday, November 13th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.25). The business had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.06 million. On average, sell-side analysts expect that Clene Inc. will post -5.19 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Clene in a report on Tuesday, October 14th. D. Boral Capital restated a “buy” rating and set a $23.00 price target on shares of Clene in a research report on Wednesday, December 10th. UBS Group reiterated a “buy” rating on shares of Clene in a research report on Wednesday, December 3rd. Finally, Benchmark reissued a “buy” rating on shares of Clene in a research note on Thursday, December 4th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $32.60.

Institutional Trading of Clene

A number of hedge funds have recently made changes to their positions in the stock. Scoggin Management LP increased its stake in Clene by 75.1% in the third quarter. Scoggin Management LP now owns 250,000 shares of the company’s stock valued at $1,506,000 after acquiring an additional 107,250 shares during the last quarter. Lunt Capital Management Inc. increased its position in shares of Clene by 2.5% during the 3rd quarter. Lunt Capital Management Inc. now owns 52,260 shares of the company’s stock valued at $315,000 after purchasing an additional 1,250 shares during the last quarter. Jones Financial Companies Lllp bought a new position in shares of Clene during the 3rd quarter valued at about $29,000. Finally, Jane Street Group LLC purchased a new position in shares of Clene during the 2nd quarter valued at about $47,000. 23.28% of the stock is owned by institutional investors.

Trending Headlines about Clene

Here are the key news stories impacting Clene this week:

• Positive Sentiment: Sell‑side support remains — several research firms (Benchmark, UBS, D. Boral Capital) continue to carry Buy ratings and elevated targets, which can limit downside and support rebounds. MarketBeat CLNN
• Neutral Sentiment: Institutional activity mixed — some hedge funds increased or initiated positions (e.g., Scoggin Management added shares), meaning a portion of supply is being absorbed by institutions rather than retail. MarketBeat Holdings
• Negative Sentiment: Material insider selling by a major shareholder — Ugwumba disclosed many transactions from Dec. 3–17 totaling roughly ~258k shares sold across multiple days (including a 72,748 share sale on Dec. 4 that was reported as a 12.24% position reduction). Heavy, concentrated selling from a >10% holder puts clear downward pressure and likely explains the intraday weakness. InsiderTrades Article
• Negative Sentiment: Weak recent operating results — the company missed Q3 revenue and EPS expectations (reported -$0.85 vs. consensus -$0.60; revenue essentially immaterial), keeping the story speculative and increasing sensitivity to insider flows. SEC Filing

About Clene

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).